Title : Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor)
link : Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor)
Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor)
SNO 2016 abstract: CSIG-13 ANDROGEN RECEPTOR IS INVOLVED IN GLIOBLASTOMA AND PRESENTS A POTENTIAL THERAPEUTIC TARGETSNO 2017 abstract: CSIG-24. ANDROGEN RECEPTOR IS A POTENTIAL THERAPEUTIC TARGET IN GLIOBLASTOMA
"Enzalutamide given orally (20 mg/kg three time per week) to nude mice bearing human gliomas (U78MG) resulted in reduction of 72% in tumor volume (p=0.0027) as compared to mice treated with vehicle. We hope that the results of this study together with continued laboratory efforts will lead to a new approach for the treatment of human glioblastoma."
Enzalutamide is an androgen receptor inhibitor approved by the FDA in 2012 for treatment of prostate cancer.
Thus Article Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor)
That's an article Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor) This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor) with the link address https://polennews.blogspot.com/2018/01/increased-expression-of-androgen.html
0 Response to "Increased expression of androgen receptor (AR) in GBM. Enzalutamide (androgen receptor inhibitor)"
Post a Comment